Literature DB >> 19620246

Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.

Karim Abid1, Bertrand Rochat, Paul-Gerhard Lassahn, Reto Stöcklin, Sophie Michalet, Noureddine Brakch, Jean-Francois Aubert, Bilgin Vatansever, Patricia Tella, Ingrid De Meester, Eric Grouzmann.   

Abstract

There is little information on how neuropeptide Y (NPY) proteolysis by peptidases occurs in serum, in part because reliable techniques are lacking to distinguish different NPY immunoreactive forms and also because the factors affecting the expression of these enzymes have been poorly studied. In the present study, LC-MS/MS was used to identify and quantify NPY fragments resulting from peptidolytic cleavage of NPY(1-36) upon incubation with human serum. Kinetic studies indicated that NPY(1-36) is rapidly cleaved in serum into 3 main fragments with the following order of efficacy: NPY(3-36) >> NPY(3-35) > NPY(2-36). Trace amounts of additional NPY forms were identified by accurate mass spectrometry. Specific inhibitors of dipeptidyl peptidase IV, kallikrein, and aminopeptidase P prevented the production of NPY(3-36), NPY(3-35), and NPY(2-36), respectively. Plasma kallikrein at physiological concentrations converted NPY(3-36) into NPY(3-35). Receptor binding assays revealed that NPY(3-35) is unable to bind to NPY Y1, Y2, and Y5 receptors; thus NPY(3-35) may represent the major metabolic clearance product of the Y2/Y5 agonist, NPY(3-36).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620246      PMCID: PMC2757175          DOI: 10.1074/jbc.M109.035253

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor.

Authors:  P Naveilhan; H Hassani; J M Canals; A J Ekstrand; A Larefalk; V Chhajlani; E Arenas; K Gedda; L Svensson; P Thoren; P Ernfors
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

Review 2.  The role of neuropeptide Y in cardiovascular regulation.

Authors:  P Walker; E Grouzmann; M Burnier; B Waeber
Journal:  Trends Pharmacol Sci       Date:  1991-03       Impact factor: 14.819

3.  Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa.

Authors:  Eric Grouzmann; Michel Monod; Basile Landis; Sherwin Wilk; Noureddine Brakch; Kevin Nicoucar; Roland Giger; Didier Malis; Ildiko Szalay-Quinodoz; Claudia Cavadas; Denis R Morel; Jean-Silvain Lacroix
Journal:  FASEB J       Date:  2002-05-21       Impact factor: 5.191

4.  Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.

Authors:  Mark Peek; Paul Moran; Nerissa Mendoza; Dineli Wickramasinghe; Daniel Kirchhofer
Journal:  J Biol Chem       Date:  2002-10-07       Impact factor: 5.157

Review 5.  Neuropeptide Y: multiple receptors and multiple roles in cardiovascular diseases.

Authors:  Jennifer Pons; Edward W Lee; Lijun Li; Joanna Kitlinska
Journal:  Curr Opin Investig Drugs       Date:  2004-09

6.  Hydrolysis by plasma kallikrein of fluorogenic peptides derived from prorenin processing site.

Authors:  P C Almeida; J R Chagas; M H Cezari; M A Juliano; L Juliano
Journal:  Biochim Biophys Acta       Date:  2000-06-15

7.  Prejunctional and postjunctional effects of neuropeptide Y at the noradrenergic neuroeffector junction of the perfused mesenteric arterial bed of the rat.

Authors:  T C Westfall; S Carpentier; X Chen; M C Beinfeld; L Naes; M J Meldrum
Journal:  J Cardiovasc Pharmacol       Date:  1987-12       Impact factor: 3.105

8.  Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11.

Authors:  M D Medeiros; A J Turner
Journal:  Endocrinology       Date:  1994-05       Impact factor: 4.736

9.  Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV.

Authors:  R Mentlein; P Dahms; D Grandt; R Krüger
Journal:  Regul Pept       Date:  1993-12-10

10.  Processing of apolipoprotein B-100 of human plasma low density lipoproteins by tissue and plasma kallikreins.

Authors:  A D Cardin; R L Jackson; V H Donaldson; J Chao; H S Margolius
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

View more
  18 in total

1.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

2.  Placental Neuropeptide Y ( NPY) and NPY receptors expressions and serum NPY levels in preeclampsia.

Authors:  Roongrit Klinjampa; Chantacha Sitticharoon; Xaynaly Souvannavong-Vilivong; Chanakarn Sripong; Issarawan Keadkraichaiwat; Malika Churintaraphan; Saimai Chatree; Tripop Lertbunnaphong
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-13

3.  Identification of an intracellular M17 family leucine aminopeptidase that is required for virulence in Staphylococcus aureus.

Authors:  Ronan K Carroll; Tiffany M Robison; Frances E Rivera; Jessica E Davenport; Ing-Marie Jonsson; Danuta Florczyk; Andrej Tarkowski; Jan Potempa; Joanna Koziel; Lindsey N Shaw
Journal:  Microbes Infect       Date:  2012-05-02       Impact factor: 2.700

4.  Identification of novel loci affecting circulating chromogranins and related peptides.

Authors:  Beben Benyamin; Adam X Maihofer; Andrew J Schork; Bruce A Hamilton; Fangwen Rao; Geert W Schmid-Schönbein; Kuixing Zhang; Manjula Mahata; Mats Stridsberg; Nicholas J Schork; Nilima Biswas; Vivian Y Hook; Zhiyun Wei; Grant W Montgomery; Nicholas G Martin; Caroline M Nievergelt; John B Whitfield; Daniel T O'Connor
Journal:  Hum Mol Genet       Date:  2017-01-01       Impact factor: 6.150

5.  Proteomic identification of novel plasma kallikrein substrates in the astrocyte secretome.

Authors:  Jia Liu; Ben-Bo Gao; Edward P Feener
Journal:  Transl Stroke Res       Date:  2010-08-28       Impact factor: 6.829

6.  Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment.

Authors:  B Shariat-Madar; D Kolte; A Verlangieri; Z Shariat-Madar
Journal:  Diabetes Metab Syndr Obes       Date:  2010-04       Impact factor: 3.168

Review 7.  Role of plasma kallikrein in diabetes and metabolism.

Authors:  E P Feener; Q Zhou; W Fickweiler
Journal:  Thromb Haemost       Date:  2013-05-16       Impact factor: 5.249

8.  Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients.

Authors:  Suncica Buljevic; Dijana Detel; Lara Baticic Pucar; Radovan Mihelic; Tomislav Madarevic; Branko Sestan; Jadranka Varljen
Journal:  Rheumatol Int       Date:  2013-07-18       Impact factor: 2.631

9.  In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans.

Authors:  Signe Toräng; Kirstine Nyvold Bojsen-Møller; Maria Saur Svane; Bolette Hartmann; Mette Marie Rosenkilde; Sten Madsbad; Jens Juul Holst
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-01-27       Impact factor: 3.619

10.  Micellar nanomedicine of human neuropeptide Y.

Authors:  Antonina Kuzmis; Sok Bee Lim; Esha Desai; Eunjung Jeon; Bao-Shiang Lee; Israel Rubinstein; Hayat Onyüksel
Journal:  Nanomedicine       Date:  2011-01-25       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.